Mark R Stein
Overview
Explore the profile of Mark R Stein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sleasman J, Lumry W, Hussain I, Wedner H, Harris J, Courtney K, et al.
Immunotherapy
. 2019 Oct;
11(16):1371-1386.
PMID: 31621458
This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human - klhw 20% solution (IGSC-C 20%) in participants with primary humoral immunodeficiency (PI),...
2.
Wasserman R, Melamed I, Stein M, Jolles S, Norton M, Moy J
J Clin Immunol
. 2017 Jul;
37(6):613.
PMID: 28714047
No abstract available.
3.
Wasserman R, Melamed I, Stein M, Jolles S, Norton M, Moy J
J Clin Immunol
. 2017 Mar;
37(3):301-310.
PMID: 28316003
Purpose: This phase 3, multicenter, open-label, randomized, two-period, crossover bioequivalence trial evaluated the safety, tolerability, and pharmacokinetics of intravenous immunoglobulins (IVIGs) Gammaplex 5% and Gammaplex 10% in 33 adults and...
4.
Wasserman R, Stein M, Younger M, Fatteh S, Haddad E
Ann Allergy Asthma Immunol
. 2016 May;
117(1):93-4.
PMID: 27236217
No abstract available.
5.
Wasserman R, Melamed I, Stein M, Engl W, Sharkhawy M, Leibl H, et al.
J Clin Immunol
. 2016 May;
36(6):571-82.
PMID: 27220317
Purpose: Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in...
6.
Koterba A, Stein M
Allergy Asthma Clin Immunol
. 2014 Dec;
11(1):63.
PMID: 25535489
Background: Patients with immunodeficiency diseases require lifelong treatment with immunoglobulin (Ig), yet few studies have vetted dosing strategies and effectiveness of Ig in older patient populations. Patients requiring subcutaneous (SC)...
7.
Jolles S, Stein M, Longhurst H, Borte M, Ritchie B, Sturzenegger M, et al.
Biol Ther
. 2014 Jan;
1:3.
PMID: 24392293
Subcutaneous immunoglobulin (SCIG) treatment provides stable serum immunoglobulin G (IgG) levels, is associated with fewer systemic adverse events than intravenous immunoglobulin (IVIG) treatment, and offers the convenience of home therapy....
8.
Wasserman R, Melamed I, Stein M, Gupta S, Puck J, Engl W, et al.
J Allergy Clin Immunol
. 2012 Aug;
130(4):951-7.e11.
PMID: 22846381
Background: Subcutaneous immunoglobulin (IGSC) replacement therapy for primary immunodeficiency (PI) is equally efficacious to intravenous immunoglobulin (IGIV), induces fewer systemic reactions, and may be self-infused. Limited SC infusion volumes and...
9.
Stein M, Koterba A, Rodden L, Berger M
Postgrad Med
. 2011 Sep;
123(5):186-93.
PMID: 21904101
Background: Subcutaneous immunoglobulin (SCIG) is as effective as intravenous immunoglobulin (IVIG) in minimizing infections in patients with primary immunodeficiency diseases (PIDD) and is associated with fewer systemic adverse events (AEs)....
10.
Wasserman R, Melamed I, Nelson Jr R, Knutsen A, Fasano M, Stein M, et al.
Clin Pharmacokinet
. 2011 May;
50(6):405-14.
PMID: 21553933
Background And Objectives: Immunoglobulin replacement is a standard therapy for patients with primary immunodeficiencies. Subcutaneous administration of immunoglobulin offers more constant IgG levels than intravenous administration and simplifies administration for...